News & Press Releases

Press Releases

The Insides Company’s Chyme Reinfusion System features in latest British Journal of Surgery Article

Press Release Source: The Insides Company Limited On: 9:00am Auckland, Monday 20th April 2020 Companies: The Insides Company Limited The Insides Company is delighted to announce the recent publication of the article, “Novel chyme reinfusion device for gastrointestinal fistulas and stomas: feasibility study” under the British Journal of Surgery (BJS), featuring the company’s therapeutic chyme reinfusion solution for the management…
William Lin
April 20, 2020
News

The remarkable Kiwi surgeon who’s helped hundreds in Nepal

This story was originally published on Newsroom.co.nz and is republished with permission. Eloise Gibson is Newsroom's environment and science editor. She's written for the New Zealand Herald, Stuff.co.nz, The Listener, and BBC Future.com. Twitter: @eloise_gibson.   New Zealand surgeon Ian Bissett at Patan, Nepal, in 2010 with a patient he had operated on just three previously at a surgical camp. Photo: Colin…
William Lin
January 31, 2020
Press Releases

The Insides Company Receives ISO13485 Certification and CE Mark Approval for its Chyme Reinfusion Medical Devices

Press Release Source: The Insides Company Ltd On: 12:00PM, 31st January 2020   The Insides Company has received ISO13485 certification and CE mark approval for its chyme reinfusion therapeutic medical device solution, meaning it is now cleared for marketing in Europe and the UK. The Insides Company received ISO 13485 certification following an audit by TÜV SÜD.ISO 13485 is an…
William Lin
January 30, 2020
Press Releases

The Insides Company rebranded from Surgical Design Studio

Press Release Source: The Insides Company Ltd On: 12:00 PM, 13th December 2019 Companies: The Insides Company, Surgical Design Studio   Surgical Design Studio, a medical device company developing a chyme reinfusion therapeutic solution announces the complete rebranding to The Insides Company, featuring the unveiling of a new name, logo and website. The rebranding initiative reflects the company’s vision “to…
William Lin
December 13, 2019
News

The Insides System Cleared for Sale and Commercially Available in New Zealand

The Insides Company is pleased to announce that The Insides™ Systemfi, a therapeutic solution for the effective chyme reinfusion treatment of enteroatmospheric fistulas and high output enterostomies, is now cleared for sale and commercially available in New Zealand. This important commercial milestone follows the completion of the device’s IEC 60601 certification for the safety and performance of medical electrical equipment,…
William Lin
October 21, 2019
News

$4.3 million raised by The Insides Company, thanks to Icehouse Ventures

AUCKLAND, August 1, 2019, Medical device developer The Insides Company (TICL) (previously Surgical Design Studio), which designs transformative products that significantly improve the outcomes for patients with bowel cancer and inflammatory bowel disease, has today announced $4.3m has been raised in its first angel fundraising round led by Icehouse Ventures fund, “Tuhua 2.” Founded two years ago at the University…
John Davidson
August 8, 2019
Press Releases

The Insides Company Granted Breakthrough Device Designation by US FDA

Press Release Source: The Insides Company (Surgical Design Studio1) On: Monday 10 June 2019 Companies: Surgical Design Studio The Insides Company (TICL) (previously Surgical Design Studio), a provider of innovative products for gastrointestinal diseases, today announces its medical devices have been granted Breakthrough Device designation by the United States Food and Drug Administration (FDA). This appears to be the first…
John Davidson
June 10, 2019
Press Releases

The Insides Company Appoints Commercialisation CEO

Press Release Source: The Insides Company Limited (Surgical Design Studio1.) On: 4:00pm Auckland, Wednesday 8 May 2019 Companies: The Insides Company Limited (previously Surgical Design Studio Limited) The Insides Company (TICL), a provider of innovative medical devices for gastrointestinal surgery, today announces the appointment of Garth Sutherland as Chief Executive Officer to lead the company in its commercialisation phase of…
John Davidson
May 8, 2019

Blog

Please Don’t Delay, Talk to The Insides Company Today

Since launching, we have received a number of enquiries about our Chyme Reinfusion System from Clinicians who have patients with High Output Enteroatmospheric Fistulas (EAF), only to then be updated that the patient has suffered a severe complication and is no longer available for treatment. High output EAFs are catastrophic conditions with high mortality rates, from 20% to 30% (1).

Click to read more…

What is an Enterocutaneous Fistula and Enteroatmospheric Fistula?

An enterocutaneous fistula (ECF) or an enteroatmospheric fistula (EAF) is a catastrophic complication requiring intense care and optimized nutrition to help accelerate the patient’s journey to recovery.

An ECF is an abnormal connection or tract (fistula) that develops between the intestine (entero) and the skin (cutaneous). An EAF is a special type of ECF where the intestines surface through the skin, exposing the intestines to the atmosphere and external environment (atmospheric).

Click to read more…

What is Chyme?

Chyme (“/kʌɪm/”) is the medical term used to describe the pulpy and semi-fluid composition of partly undigested food, fluid, stomach acid/gastric juices (hydrochloric acid), and digestive enzymes such as pancreatic enzymes and bile. Chyme is initially created in the stomach through both mechanical and chemical processes and passed on into the small intestine for absorption. Chyme is a critical component of gut health and the digestive system. It contains valuable digestive secretions crucial in the maintenance of fluid, electrolyte balance and gut biome.

Click to read more…

What is Chyme Reinfusion?

Chyme Reinfusion (CR) is a practice in the management of patients with High-Output Enterocutaneous Fistulas, and High-Output Enterostomies. Chyme Reinfusion enables patients to reestablish oral feeding and wean off the Parenteral Nutrition (PN) in as little as 3 days (1), resulting in significant health economic benefits and improvements in quality of life (QoL).

Click to read more…

Case Studies

Ray’s Story, Enteroatmospheric Fistula Patient Journey

Ray, a father and grandfather, had been physically active, regularly helped in his community and loved his job as a barber.

Following a routine operation for a small bowel obstruction, Ray developed an Enteroatmospheric Fistula1. Complications including malnutrition and sepsis resulted in a serious deterioration of Ray’s health and many months spent in hospital.

Click to read more…